Vitrolife is the First Company in China to Receive Regulatory Approval for an Entire IVF Culture Media Portfolio
GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR) is the first company to receive regulatory approval for an entire IVF culture media portfolio in China. With the approval from Chinese SFDA (State Food and Drug Administration), Vitrolife can now provide a unique level of compliance to the IVF community with products covering all steps of an IVF treatment.